416 related articles for article (PubMed ID: 8294865)
1. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides.
Mellins E; Cameron P; Amaya M; Goodman S; Pious D; Smith L; Arp B
J Exp Med; 1994 Feb; 179(2):541-9. PubMed ID: 8294865
[TBL] [Abstract][Full Text] [Related]
2. Invariant-cognate peptide exchange restores class II dimer stability in HLA-DM mutants.
Monji T; McCormack AL; Yates JR; Pious D
J Immunol; 1994 Nov; 153(10):4468-77. PubMed ID: 7525705
[TBL] [Abstract][Full Text] [Related]
3. The requirement for DM in class II-restricted antigen presentation and SDS-stable dimer formation is allele and species dependent.
Stebbins CC; Loss GE; Elias CG; Chervonsky A; Sant AJ
J Exp Med; 1995 Jan; 181(1):223-34. PubMed ID: 7807005
[TBL] [Abstract][Full Text] [Related]
4. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
Ramachandra L; Kovats S; Eastman S; Rudensky AY
J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
[TBL] [Abstract][Full Text] [Related]
5. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide.
Sherman MA; Weber DA; Jensen PE
Immunity; 1995 Aug; 3(2):197-205. PubMed ID: 7648393
[TBL] [Abstract][Full Text] [Related]
6. Predominant HLA-class II bound self-peptides of a hematopoietic progenitor cell line are derived from intracellular proteins.
Harris PE; Maffei A; Colovai AI; Kinne J; Tugulea S; Suciu-Foca N
Blood; 1996 Jun; 87(12):5104-12. PubMed ID: 8652823
[TBL] [Abstract][Full Text] [Related]
7. Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.
Patil NS; Pashine A; Belmares MP; Liu W; Kaneshiro B; Rabinowitz J; McConnell H; Mellins ED
J Immunol; 2001 Dec; 167(12):7157-68. PubMed ID: 11739539
[TBL] [Abstract][Full Text] [Related]
8. Impaired antigen presentation by murine I-Ad class II MHC molecules expressed in normal and HLA-DM-defective human B cell lines.
Weenink S; Averdunk H; Boston T; Boswarva V; Guery JC; Adorini L; Mellins E; McCluskey J; Gautam AM
Int Immunol; 1997 Jun; 9(6):889-96. PubMed ID: 9199972
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides.
Avva RR; Cresswell P
Immunity; 1994 Dec; 1(9):763-74. PubMed ID: 7895165
[TBL] [Abstract][Full Text] [Related]
10. Mediation by HLA-DM of dissociation of peptides from HLA-DR.
Sloan VS; Cameron P; Porter G; Gammon M; Amaya M; Mellins E; Zaller DM
Nature; 1995 Jun; 375(6534):802-6. PubMed ID: 7596415
[TBL] [Abstract][Full Text] [Related]
11. Editing of the HLA-DR-peptide repertoire by HLA-DM.
Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
[TBL] [Abstract][Full Text] [Related]
12. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways.
Teyton L; O'Sullivan D; Dickson PW; Lotteau V; Sette A; Fink P; Peterson PA
Nature; 1990 Nov; 348(6296):39-44. PubMed ID: 2234057
[TBL] [Abstract][Full Text] [Related]
13. Intracellular and cell surface heterotypic associations of human leukocyte antigen-DR and human invariant chain.
Triantafilou K; Triantafilou M; Wilson KM; Cherry RJ; Fernandez N
Hum Immunol; 1999 Nov; 60(11):1101-12. PubMed ID: 10600008
[TBL] [Abstract][Full Text] [Related]
14. Acquisition of peptides by MHC class II polypeptides in the absence of the invariant chain.
Hitzel C; van Endert P; Koch N
J Immunol; 1995 Feb; 154(3):1048-56. PubMed ID: 7822782
[TBL] [Abstract][Full Text] [Related]
15. Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant.
Sette A; Ceman S; Kubo RT; Sakaguchi K; Appella E; Hunt DF; Davis TA; Michel H; Shabanowitz J; Rudersdorf R
Science; 1992 Dec; 258(5089):1801-4. PubMed ID: 1465617
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of peptide binding to DR molecules by a leupeptin-induced invariant chain fragment.
Demotz S; Danieli C; Wallny HJ; Majdic O
Mol Immunol; 1994 Aug; 31(12):885-93. PubMed ID: 8065372
[TBL] [Abstract][Full Text] [Related]
17. DR alpha: E beta heterodimers in DRA transgenic mice hinder expression of E alpha: E beta molecules and are more efficient in antigen presentation.
Trembleau S; Giacomini P; Guéry JC; Setini A; Hammer J; Sette A; Appella E; Adorini L
Int Immunol; 1995 Dec; 7(12):1927-38. PubMed ID: 8746562
[TBL] [Abstract][Full Text] [Related]
18. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides.
Riberdy JM; Newcomb JR; Surman MJ; Barbosa JA; Cresswell P
Nature; 1992 Dec; 360(6403):474-7. PubMed ID: 1448172
[TBL] [Abstract][Full Text] [Related]
19. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM.
Weber DA; Evavold BD; Jensen PE
Science; 1996 Oct; 274(5287):618-20. PubMed ID: 8849454
[TBL] [Abstract][Full Text] [Related]
20. Invariant chain prevents the HLA-DR-restricted presentation of a cytosolic peptide.
Long EO; LaVaute T; Pinet V; Jaraquemada D
J Immunol; 1994 Aug; 153(4):1487-94. PubMed ID: 8046228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
